Literature DB >> 947654

Antipyrine: radioimmunoassay in plasma and saliva following administration of a high dose and a low dose.

R L Chang, A W Wood, W R Dixon, A H Conney, K E Anderson, J Eiseman, A P Alvares.   

Abstract

A simple and senstitive radioimmunoassay has been developed for the determination of antipyrine levels in plasma and saliva of man. Antiserum to antipyrine was obtained from rabbits immunized with an immunogen prepared by covalently coupling N-(4-antipyrinyl)-succinamic acid to bovine serum albumin (BSA). The radioimmunoassay can detect antipyrine levels as low as 10 ng/ml of plasma or saliva, using a 0.1-ml sample. This contrasts with the sensitivity of a commonly used spectrophotometric method that can measure about 4,000 ng/ml using a 2-ml plasma sample. Agreement between the radioimmunoassay and spectrophotometric assay of antipyrine was excellent for plasma (r = 0.98) and salvia (r =0.97) when samples were analyzed from 6 subjects receiving 18 mg/kg of antipyrine. The correlation between plasma and saliva antipyrine half-lives using the radioimmunoassay and an 18 mg/kg dose of antipyrine was r = 0.90 (p less than 0.005). After a dose of 1.8 mg/kg of antipyrine, the drug disappeared monoexponentially from plasma and saliva for at least 51 hr, and the correlation between plasma half-life and saliva half-life was r = 0.97 (p less than 0.001) in the 6 subjects. Excellent agreement was also observed between half-lives after the high and low doses of antipyrine (r = 0.99, p less than 0.001 for plasma and r = 0.98, p less than 0.001 for saliva).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 947654     DOI: 10.1002/cpt1976202219

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

Review 1.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

2.  Effect of vitamin C supplement on antipyrine disposition in man.

Authors:  J B Houston
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

Review 3.  Oral absorption and secretion of drugs.

Authors:  C F Speirs
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

Review 4.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 5.  Clinical implications of enzyme induction and enzyme inhibition.

Authors:  B K Park; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

6.  Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Authors:  M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

Review 7.  Assessment of methods to identify sources of interindividual pharmacokinetic variations.

Authors:  E S Vesell; M B Penno
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

8.  Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.

Authors:  M Danhof; A van Zuilen; J K Boeijinga; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 9.  Noninvasive assessment of microsomal enzyme activity in occupational medicine: present state of knowledge and future perspectives.

Authors:  M Døssing
Journal:  Int Arch Occup Environ Health       Date:  1984       Impact factor: 3.015

10.  Nutrition-endocrine interactions: induction of reciprocal changes in the delta 4-5 alpha-reduction of testosterone and the cytochrome P-450-dependent oxidation of estradiol by dietary macronutrients in man.

Authors:  A Kappas; K E Anderson; A H Conney; E J Pantuck; J Fishman; H L Bradlow
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.